Larimar Therapeutics
LRMR
38 hedge funds and large institutions have $207M invested in Larimar Therapeutics in 2020 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 11 increasing their positions, 6 reducing their positions, and 5 closing their positions.
83% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 6
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
24% more capital invested
Capital invested by funds: $166M → $207M (+$40.6M)
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
4.37% more ownership
Funds ownership: 84.33% → 88.7% (+4.4%)
3% more funds holding
Funds holding: 37 → 38 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
+$3.45M |
| 2 |
Janus Henderson Group
London,
|
+$2.07M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.77M |
| 4 |
Verition Fund Management
Greenwich,
Connecticut
|
+$658K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$588K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$693K |
| 2 |
O
OrbiMed
New York
|
-$600K |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$596K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$259K |
| 5 |
SCM
Sio Capital Management
New York
|
-$224K |
LRMR Hedge Fund Activity: Q3 2020 in Review
38 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Larimar Therapeutics (LRMR) for Q3 2020, worth a combined $207M — up 24% from $166M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new LRMR positions and 5 closed out — a net gain of 1 holder — while 11 added to existing stakes and 6 trimmed.
The largest buyer was Logos Global Management, adding an estimated $3.45M. The largest seller was Sphera Funds Management, cutting an estimated $693K.
- 38 institutional investors held Larimar Therapeutics (LRMR) as of Q3 2020, up from 37 in Q2 2020.
- Funds reported $207M of Larimar Therapeutics stock for Q3 2020, up 24% quarter-over-quarter.
- 6 funds opened new Larimar Therapeutics positions in Q3 2020 and 5 closed out, a net change of +1 holder.
- The largest Larimar Therapeutics buyer in Q3 2020 was Logos Global Management, an estimated $3.45M added.
- The largest Larimar Therapeutics seller in Q3 2020 was Sphera Funds Management, an estimated $693K sold.
Based on aggregated 13F filings for Q3 2020.